Chiquita Brooks-LaSure

some of the ways that we changed it were really about changing the structure and this year is actually the best benefit for people and that is that there is for the first time a two thousand dollar cap on prescription drug costs for the medicare population and this is huge because as we all know prescription drug costs that people are paying out of pocket have really affected people.

And there were seniors who still were paying something like $18,000 a year for their prescription drug costs. So this is a sea change. But part of the way that we were able to pay for that was through negotiating prescription drug crisis and in the Medicare program. And it wasn't for all of them. The law really outlined taking the most expensive drugs.

And there were seniors who still were paying something like $18,000 a year for their prescription drug costs. So this is a sea change. But part of the way that we were able to pay for that was through negotiating prescription drug crisis and in the Medicare program. And it wasn't for all of them. The law really outlined taking the most expensive drugs.

And there were seniors who still were paying something like $18,000 a year for their prescription drug costs. So this is a sea change. But part of the way that we were able to pay for that was through negotiating prescription drug crisis and in the Medicare program. And it wasn't for all of them. The law really outlined taking the most expensive drugs.

And each year, more prescription drugs are added to the list that CMS can negotiate. And last year, CMS negotiated lower costs for 10 of the costliest drugs to the Medicare population. And that year alone, we estimated that in one year we'll save $1.5 billion for Medicare beneficiaries and then $6 billion overall. So those are just a little bit at a high level of what the Inflation Reduction Act

And each year, more prescription drugs are added to the list that CMS can negotiate. And last year, CMS negotiated lower costs for 10 of the costliest drugs to the Medicare population. And that year alone, we estimated that in one year we'll save $1.5 billion for Medicare beneficiaries and then $6 billion overall. So those are just a little bit at a high level of what the Inflation Reduction Act

And each year, more prescription drugs are added to the list that CMS can negotiate. And last year, CMS negotiated lower costs for 10 of the costliest drugs to the Medicare population. And that year alone, we estimated that in one year we'll save $1.5 billion for Medicare beneficiaries and then $6 billion overall. So those are just a little bit at a high level of what the Inflation Reduction Act

put into law, it still continues. It continues to be the law of the land. Right before I left, we announced the next 15 drugs, and CMS should be negotiating those as we speak. And so we'll see how the new administration, how the current administration moves forward with that, because it is the law of the land. So then yesterday there was an executive order. And I would say a couple of things.

put into law, it still continues. It continues to be the law of the land. Right before I left, we announced the next 15 drugs, and CMS should be negotiating those as we speak. And so we'll see how the new administration, how the current administration moves forward with that, because it is the law of the land. So then yesterday there was an executive order. And I would say a couple of things.

put into law, it still continues. It continues to be the law of the land. Right before I left, we announced the next 15 drugs, and CMS should be negotiating those as we speak. And so we'll see how the new administration, how the current administration moves forward with that, because it is the law of the land. So then yesterday there was an executive order. And I would say a couple of things.

You know, there are different ways to approach prescriptions, lowering prescription drug costs. Every administration has a right to put forth their own vision of what they think should be done. There really wasn't a lot of detail in the executive order yesterday to really know. It doesn't say where the administration wants to lower costs. It doesn't say the Medicare population.

You know, there are different ways to approach prescriptions, lowering prescription drug costs. Every administration has a right to put forth their own vision of what they think should be done. There really wasn't a lot of detail in the executive order yesterday to really know. It doesn't say where the administration wants to lower costs. It doesn't say the Medicare population.

You know, there are different ways to approach prescriptions, lowering prescription drug costs. Every administration has a right to put forth their own vision of what they think should be done. There really wasn't a lot of detail in the executive order yesterday to really know. It doesn't say where the administration wants to lower costs. It doesn't say the Medicare population.

It doesn't say Medicaid. It doesn't say the commercial market. So, you know, not a lot of specifics about what the approach might be. There's an indication of potentially doing rulemaking if drug companies don't come to the table voluntarily. You know, we'll see what the industry says in terms of their response to the executive order. But I would say, you know, two things.

It doesn't say Medicaid. It doesn't say the commercial market. So, you know, not a lot of specifics about what the approach might be. There's an indication of potentially doing rulemaking if drug companies don't come to the table voluntarily. You know, we'll see what the industry says in terms of their response to the executive order. But I would say, you know, two things.

It doesn't say Medicaid. It doesn't say the commercial market. So, you know, not a lot of specifics about what the approach might be. There's an indication of potentially doing rulemaking if drug companies don't come to the table voluntarily. You know, we'll see what the industry says in terms of their response to the executive order. But I would say, you know, two things.

One, again, the law of the land says that Medicare should be negotiating. And we'll see, does the administration move forward with implementing the law? And it will be a process, right, of how they approach it. But this is important to seniors.

One, again, the law of the land says that Medicare should be negotiating. And we'll see, does the administration move forward with implementing the law? And it will be a process, right, of how they approach it. But this is important to seniors.

One, again, the law of the land says that Medicare should be negotiating. And we'll see, does the administration move forward with implementing the law? And it will be a process, right, of how they approach it. But this is important to seniors.

And then secondly, you know, well, there isn't enough detail in what was announced yesterday, I say, I think, to really have a perspective on whether or not it's going to be effective or or whether we'll see any changes to prescription drug prices.